Register Login

EyePoint Pharmaceuticals Inc (EYPT)

(30% Negative) EyePoint, Inc. (EYPT) Announces Delay in Conference Trials for San Francisco on Tuesday Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 7, 2026, 12:07 p.m.

    📋 EyePoint, Inc. (EYPT) - Clinical Trial Update

    Filing Date: 2026-01-07

    Accepted: 2026-01-07 07:05:26

    Event Type: Clinical Trial Update

    Event Details:

    EyePoint Pharmaceuticals Inc (EYPT) Announces Clinical Trial Update EyePoint Pharmaceuticals Inc (EYPT) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: Conference, underway
    • Diseases/Conditions: San Francisco on Tuesday, a milestone-rich year
    • Clinical Stage: Phase 3, Phase 3 program
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Patient Enrollment, Regulatory Process
    • Collaboration: FDA
    • Updated Timeline: Q1 2026
      • anticipated in mid-2026
      • expected in the first quarter of 2026
      • expected in Q1 2026

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: EyePoint Pharmaceuticals Inc
    • CIK: 0001314102
    • Ticker Symbol: EYPT
    • Period End Date: 2026-01-07
    • Document Type: 8-K

Search

News categories